Keeping up with regulatory compliance in clinical trials transparency (CTT) is demanding. Sponsors need to navigate overlapping, multi-jurisdictional obligations, each with distinct timelines, data formats, and requirements for confidential information1–3. This challenge, however, extends beyond the technical work of anonymization and redaction. The language used to describe anonymization approaches in submission documents is itself subject to regulatory scrutiny, and preferred terminology is not consistent across frameworks or stable over time. Furthermore, the regulatory landscape is ever-changing, and what constitutes clear and appropriate documentation shifts alongside it. This blog examines how terminology and documentation standards in CTT are shifting across major regulatory frameworks, and what organizations can do to ensure their documentation keeps pace with changing expectations.
How CTT Regulations Continue to Evolve
Three regulatory frameworks define the current landscape for clinical data transparency: the European Union’s Clinical Trials Regulation (EU CTR)4 and EMA Policy 00705, and Health Canada’s Public Release of Clinical Information (PRCI)6. These regulations are designed to make the evidence underpinning regulatory decisions publicly accessible, thereby enabling independent scientific scrutiny, maintaining public trust in the medicines approval process, and preventing selective reporting. While each of these has distinct requirements for how clinical data is made publicly available after medicine approval decisions are made, they all require that personal and commercially confidential information is protected.
Requirements continue to evolve through updated guidance, regulatory feedback, and shifting interpretations of key concepts. The language used to describe anonymization in submissions, including how techniques are named, justified, and presented, is itself subject to changing expectations. These changes are shaped by agency feedback, evolving data protection principles, and the practical lessons regulators have drawn from reviewing submissions.
Each of the major frameworks is moving in its own direction. Under EMA Policy 0070, standards for justifying the removal of commercially confidential information continue to be refined, and expectations around the clarity and consistency of anonymization documentation have increased5,7. The EU CTR, meanwhile, operates in a context shaped by the General Data Protection Regulation (GDPR), which impacts how data protection principles must be articulated in submission documents8. Health Canada’s PRCI framework takes a distinct approach, requiring structured anonymization and risk assessments that differ in important ways from those in Europe6. As such, an approach to anonymization that is compliant under one framework may require a different framing under another.
The Terminology Problem
Terminology in CTT is not just a matter of style. The language used to describe anonymization approaches determines how clearly the underlying rationale is communicated and how robustly it can be defended if regulators raise questions. The preferred language indicates more general approaches to anonymization and data protection. These approaches can be broadly characterized into two camps. Formalist approaches prefer rigorous, context-independent criteria that are universally applicable. Pragmatic approaches, on the other hand, hold that anonymization is inherently context-dependent. These differences have resulted in inconsistent terminology across the field. Concepts like “quasi-identifier” lack standardized definitions, and terms are often used with technique-specific meanings rather than widely accepted ones9.
These contrasting approaches are also reflected in CTT-related regulation. Under GDPR, the concept of anonymous data is defined in contextual terms, and anonymization must protect against “means reasonably likely” to be used for identification10. This is a pragmatic approach that applies a principles-based standard. By contrast, Health Canada’s PRCI mandates structured, technique-specific anonymization documentation and a fixed risk threshold6, which is closer to a rule-based, formalist approach. In both cases, the language used to describe anonymization decisions shapes how reviewers interpret and evaluate the submission. As such, inconsistencies or outdated terminology can result in non-compliance even when the underlying anonymization is carried out effectively.
Understanding Regulatory Priorities
It is important to recognize that regulatory agencies are not primarily concerned with the specific words used in a submission. They are more concerned with whether the anonymization itself is robust, whether the risk of re-identification has been reduced, and whether data utility has been preserved. A submission that achieves all of these things but uses imprecise or inconsistent language will always be in a stronger position than one with polished terminology but weak underlying methodology.
However, this doesn’t mean that terminology cannot have a significant impact. When the language used to describe an anonymization approach is unclear or inconsistent, it raises questions about the standard of the methodology itself. In particular, if the terminology isn’t aligned with the conceptual framework of the regulatory guidance, reviewers may find it harder to assess whether the anonymization meets the required standard. This can result in sponsors finding themselves unable to provide a clear and consistent defense if the submission is challenged.
Keeping Pace with Regulatory Change
For many organizations, keeping pace with a changing regulatory environment is an ongoing challenge. Teams managing submissions across multiple jurisdictions, often under cost and time pressure, rarely have the resources to track evolving guidance across all major frameworks simultaneously. Specialist CTT expertise can provide essential guidance for sponsors and organizations looking to streamline their operations and ensure ongoing compliance. Dedicated CTT professionals, whose work is focused exclusively on disclosure, anonymization, and de-identification, maintain ongoing awareness of regulatory developments and track the more subtle shifts in agency expectations.
In practice, this expertise is applied across the full range of activities that determine the quality of a submission. It informs the development of anonymization reports and submission documentation that reflect current best practice. CTT specialists can ensure that terminology is consistent and accurate across all documents in large, complex reports. Instem’s specialists bring deep knowledge of what regulators expect and how those expectations are shifting.
Alongside expert-led services, Instem’s BlurTM platform provides the technological infrastructure for scalable, compliant anonymization. Blur supports the consistent application of anonymization techniques across large volumes of clinical data and enables simulated disclosure events and anonymization quality control checks to validate strategies before submission. Delivery is flexible: organizations can choose a fully outsourced model, a hybrid approach that retains internal control over specific elements, or a mixture of these approaches.
Conclusion
The regulatory frameworks governing CTT will continue to evolve, and the terminology and documentation standards they expect will evolve with them. Organizations that don’t keep pace risk their practices drifting out of step with regulatory thinking. Those best positioned in this landscape have access to expertise that keeps a finger on the pulse of regulatory shifts, removing pressure from internal teams and reducing risk throughout the submission process and beyond.
To find out how Instem’s specialist CTT team can support your anonymization and disclosure workflows, contact us today or request a consultation.
References
1. Review of transparency rules for the EU Clinical Trials Information System (CTIS) | European Medicines Agency (EMA). May 3, 2023. Accessed May 13, 2026. https://www.ema.europa.eu/en/news/review-transparency-rules-eu-clinical-trials-information-system-ctis
2. Research transparency requirements for clinical trials. Health Research Authority. Accessed May 13, 2026. https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/clinical-trial-regulations-reform/guidance-on-changes-to-the-clinical-trials-regulations/research-transparency-requirements-for-clinical-trials/
3. NIH Clinical Trial Reforms and the Evolving Research Transparency Landscape. May 7, 2026. Accessed May 13, 2026. https://www.srainternational.org/blogs/srai-news/2026/05/07/nih-clinical-trial-reforms-research-transparency
4. Revised transparency rules for the EU Clinical Trials Information System (CTIS) | European Medicines Agency (EMA). October 6, 2023. Accessed May 13, 2026. https://www.ema.europa.eu/en/news/revised-transparency-rules-eu-clinical-trials-information-system-ctis
5. European Medicines Agency GT. External Guidance on the Implementation of the European Medicines Agency Policy on the Publication of Clinical Data for Medicinal Products for Human Use. 2018.
6. Canada H. Public Release of Clinical Information: guidance document. November 30, 2021. Accessed May 13, 2026. https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/profile-public-release-clinical-information-guidance/document.html
7. Navigating the New EMA Policy 0070 Step 2: A New Era for Clinical Trial Transparency – Life Science Software – Drug Research & Development. Accessed May 13, 2026. https://www.instem.com/navigating-the-new-ema-policy-0070-step-2-a-new-era-for-clinical-trial-transparency/
8. Nolan IM, Farrow T, Kacha R. Preparing for data transparency requirements of the new EU CTR. Regul Rapp. 2021;18(6):3.
9. Gadotti A, Rocher L, Houssiau F, Creţu AM, De Montjoye YA. Anonymization: The imperfect science of using data while preserving privacy. Sci Adv. 2024;10(29):eadn7053.
10. Recital 26 – Not Applicable to Anonymous Data. General Data Protection Regulation (GDPR). Accessed May 13, 2026. https://gdpr-info.eu/recitals/no-26/
